Free Trial
NASDAQ:URGN

UroGen Pharma (URGN) Stock Price, News & Analysis

UroGen Pharma logo
$11.90 -0.23 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$12.14 +0.24 (+2.02%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About UroGen Pharma Stock (NASDAQ:URGN)

Key Stats

Today's Range
$11.77
$12.37
50-Day Range
$9.27
$12.13
52-Week Range
$9.03
$20.70
Volume
364,524 shs
Average Volume
491,784 shs
Market Capitalization
$548.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.20
Consensus Rating
Buy

Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Remove Ads

UroGen Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

URGN MarketRank™: 

UroGen Pharma scored higher than 80% of companies evaluated by MarketBeat, and ranked 197th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    UroGen Pharma has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    UroGen Pharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about UroGen Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for UroGen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of UroGen Pharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of UroGen Pharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about UroGen Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    27.50% of the float of UroGen Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    UroGen Pharma has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in UroGen Pharma has recently decreased by 1.13%, indicating that investor sentiment is improving.
  • Dividend Yield

    UroGen Pharma does not currently pay a dividend.

  • Dividend Growth

    UroGen Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.50% of the float of UroGen Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    UroGen Pharma has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in UroGen Pharma has recently decreased by 1.13%, indicating that investor sentiment is improving.
  • News Sentiment

    UroGen Pharma has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for UroGen Pharma this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,900.00 in company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of UroGen Pharma is held by insiders.

  • Percentage Held by Institutions

    91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about UroGen Pharma's insider trading history.
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Stock News Headlines

HC Wainwright Lowers Earnings Estimates for UroGen Pharma
What Trump’s planning next
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
UroGen Pharma price target lowered to $55 from $64 at H.C. Wainwright
UroGen Pharma sees FY25 operating expenses $215M-$225M
See More Headlines

URGN Stock Analysis - Frequently Asked Questions

UroGen Pharma's stock was trading at $10.65 at the start of the year. Since then, URGN shares have increased by 11.7% and is now trading at $11.90.
View the best growth stocks for 2025 here
.

UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings results on Monday, March, 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by $0.11. The business had revenue of $24.57 million for the quarter, compared to analysts' expectations of $25.25 million.

UroGen Pharma (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

UroGen Pharma's top institutional investors include RTW Investments LP (16.35%), Adage Capital Partners GP L.L.C. (12.49%), Toronto Dominion Bank (7.46%) and Toronto Dominion Bank (7.46%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith.
View institutional ownership trends
.

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that UroGen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
3/10/2025
Today
3/24/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.20
High Stock Price Target
$55.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+220.7%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-102,240,000.00
Net Margins
-129.11%
Pretax Margin
-124.59%

Debt

Sales & Book Value

Annual Sales
$90.40 million
Price / Cash Flow
N/A
Book Value
($2.78) per share
Price / Book
-4.28

Miscellaneous

Free Float
22,258,000
Market Cap
$548.98 million
Optionable
Optionable
Beta
1.12

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:URGN) was last updated on 3/24/2025 by MarketBeat.com Staff
From Our Partners